38 results about "Trypanosoma cruzi" patented technology

The present invention relates to certain nitroimidazole compounds, which have interesting pharmaceutical properties. In particular, the compounds are useful in the treatment and/or prevention of infections such as those caused by Mycobacterium tuberculosis, Trypanosoma cruzi or Leishmania donovani. The invention also relates to pharmaceutical compositions containing the compounds, as well as processes for their preparation.

Molecular targets are identified in T. cruzi suitable for use in diagnosis of Chagas disease, drug development, and vaccines, including live vaccines.

Transfusion of contaminated blood has become the major route of transmission for Chagas' disease. Current screening tests are insensitive and yield conflicting results, while confirmatory assays do not exist. The present invention relates to antigens and their use for serological diagnosis of Chagas' disease. More specifically, the present invention concerns assays which are able to reliably and accurately detect the presence of antibodies to various specific antigens of Trypanosoma cruzi in a highly sensitive and specific manner.

It is intended to provide a method of diagnosing infection with Chagas disease by screening a trypanocidal drugs for Trypanosoma cruzi which is the pathogen of Chagas disease. Using a flavin protein TcOYE specific to Trypanosoma cruzi, a trypanocidal drugs effective against Trypanosoma cruzi is screened. Using the gene sequence of TcOYE and an antibody therefor, infection with Trypanosoma cruzi is diagnosed.

The invention relates to the field of parasite detection, and discloses a parasite detection kit and a detection method thereof. A nucleic acid reaction system of the parasite detection kit internallycomprises one or more nucleic acid amplification primer pairs for amplifying nucleotide sequences of DNA of trypanosome, leishmania, leishmania braziliensis, chagasi leishmania, Trypanoma cruzi, Trypanoma rangeli, leishmania, leishmania mexicana or leishmania amazonensis, panamensis leishmania donovani, guyanensis leishmania, or peruviana leishmania. The detection method comprises the steps thatthe one or more nucleic acid amplification primer pairs are used for a nucleic acid amplification reaction, and existence of the DNA of parasites is detected by detecting specific amplicons of the nucleic acid amplification primer pairs. Compared with a PCR, detecting through a RPA amplification mode is conducted in constant-temperature and simple equipment, the cost is low, the sensitivity is high, the parasite detection kit can be used for diagnosis of the trypanosome and the leishmania for early-infected people and infected dogs, and thus the VL incidence rate in human bodies is decreased.

A vaccine against the Chagas disease, capable of stimulating the immune response against the trans-sialidase virulence factor of the Trypanosoma Cruzi parasite, which is a multicomponent vaccine comprising: (a) an immunogenic portion formed by one or more recombinant or synthetic polypeptides or fractions of thereof and (b) one or more polynucleotides including the regions that codifying one or more immunogenic polypeptides, or a monocomponent comprising at least one component selected among an immunogenic portion formed by one or more recombinant or synthetic polypeptides or fractions of them and a group of polynucleotides including the regions codifying one or more immunogenic polypeptides derived from Trypanosoma Cruzi and pharmaceutical compositions containing said multicomponent and monocomponent vaccines, the procedures for obtaining the immunogen portion of said vaccines and the nucleic acid used in the procedure.

The invention discloses application of a reagent combination for detecting pathogens in preparation of a kit for detecting the quality of a blood product. The pathogens are selected from a pathogen group consisting of HAV, HBV, HCV, HEV, TP, HIV1, HIV2, HTLV1, HTLV2, HBOV, TTV, HCMV, B19, DENV, ZIKV, WNV, babesia, trypanosoma krusei and plasmodium, and belongs to the field of medical examination.The invention further discloses a corresponding kit and a method for detecting the quality of the blood product. By means of the kit, the lowest detection limit of pathogens is 1.0 * 10 < 3 > copies/mL, the kit has good specificity and repeatability, and an important technology is provided for screening and evaluating blood transfusion transmitted pathogens.

The invention relates to organic compounds which have interesting pharmaceutical properties. In particular, the compounds are useful in the treatment and/or prevention of infections such as those caused by Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale, Trypanosoma cruzi and parasites of the Leishmania genus such as, for example, Leishmania donovani. The invention also relates to pharmaceutical compositions containing the compounds, as well as processes for their preparation.

The current invention pertains to nitroimidazooxazine and nitroimidazooxazole analogues, their methods of preparation, and uses of the compounds as treatment for Mycobacterium tuberculosis, for use as anti-tubercular drugs, for use as anti-protozoal agents with unexpectedly high potency against Trypanosoma cruzi or Leishmania donovani, and for the treatment of other microbial infections.

Recombinant, attenuated parasites are transformed or transfected with nucleic acid molecules which provoke an immunostimulatory and protective response in subjects. Preferably, the parasite is Trypanosoma cruzi, especially strain CL-14, and the transforming nucleic acid molecule encodes for a cancer testis antigen, such as NY-ESO-1.

The invention provides specific primers for the detection of Trypanosoma cruzi with the sequences as shown in SEQ ID No.1 and SEQ ID No.2, provides specific primers for the detection of Trypanosoma brucei with the sequences as shown in SEQ ID No.3 and SEQ ID No.4, provides specific primers for the detection of Trypanosoma brucei rhodesiense with the sequences as shown in SEQ ID No.5 and SEQ ID No.6, provides specific primers for the detection of Trypanosoma brucei gambiense with the sequences as shown in SEQ ID No.7 and SEQ ID No.8, provides a probe for the detection of Trypanosoma with the sequences as shown in SEQ ID No.9 to 26, and also provides a kit and a chip for the detection of Trypanosoma. In the invention, differential diagnosis for Trypanosoma infection can be specifically carried out.

The nucleotide sequence of Tc100, a gene encoding PTc100, a new Trypanosoma antigen, and the amino acid sequence of PTc100 are described. Tc100 and PTc100, or fragments thereof, modified or otherwise, can be used directly or indirectly for the detection of Trypanosoma cruzi, or for the monitoring of the infection generated by Trypanosoma cruzi, in man or in animals.

The present invention relates to a class of novel pradimicins and analogues and derivatives thereof, including the compounds of formula A, I and 111, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof and their use to treat or prevent kinetoplastid infections and their use to manufacture a medicine to treat or prevent kinetoplastid infections, particularly infections with trypanosoma and leishmania, such as Trypanosoma brucei, Trypanosoma cruzi and Leischmania donovani. wherein R^a, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸ and R⁹ are as defined in the claim 1 or as described in detail in the description of the invention. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent kinetoplastid infections. The present invention further relates active ingredients, more specifically as medicaments for the treatment of kinetoplastid infections and pathologic conditions such as, but not limited to Trypanosomiasis, such as African trypanosomiasis, sleeping sickness, Chagas disease and leishmaniasis.

Methods for delaying and/or preventing the binding of parasites to host cells (especially mammalian host cells) are provided. The methods delay or prevent infection of host cells and the development of disease symptoms. The methods delay or prevent the parasites from locating and binding to host cells, thereby reducing the infectivity of the parasite, and allow for adjuvant drug therapy to have a longer treatment time period before infection sets in. The methods involve modifying the charge field sensed by the parasite in the vicinity of potential host cells. Such modifications may be made by exposing the parasite and/or the host cell to charge-altering agents such as charged nanoparticles.

The present disclosure provides compounds of Formula (I′), Formula (II), and Formula (III). The compounds described herein may useful in treating and/or preventing protozoan infections in a subject in need thereof, treating and/or preventing trypanosomal infections (e.g., Trypanosoma cruzi (T. cruzi) or Trypanosoma brucei infections) and/or plasmodial infections in a subject in need thereof, treating and/or preventing diseases in a subject in need thereof (e.g., Chagas disease, malaria, and/or sleeping sickness), and may be useful in treating and/or preventing infectious diseases in a subject in need thereof. Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including a compound described herein.